Clinical trials

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
Gil Awada, Laila Ben Salama, Jennifer De Cremer, Julia Katharina Schwarze, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Anne Rogiers, Peter Theuns, Johnny Duerinck, Bart Neyns

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001146; DOI: 10.1136/jitc-2020-001146
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
Yan Song, Ning Li, Qun Li, Xinjun Liang, Shu Zhang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Xiaofei Wang, Yiwei Dou, Jing Huang

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001279; DOI: 10.1136/jitc-2020-001279
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
Markus Hecht, Antoniu Oreste Gostian, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Matthias G Hautmann, Gunther Klautke, Simon Laban, Thomas Brunner, Axel Hinke, Ina Becker, Benjamin Frey, Sabine Semrau, Carol I Geppert, Arndt Hartmann, Panagiotis Balermpas, Wilfried Budach, Udo S Gaipl, Heinrich Iro, Rainer Fietkau

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001378; DOI: 10.1136/jitc-2020-001378
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
Anne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, Jared M Weiss, Taofeek K Owonikoko, Julie A Rytlewski, Jill Hood, Zhao Yang, Rajesh K Malik, Jay C Strum, Patrick J Roberts

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000847; DOI: 10.1136/jitc-2020-000847
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
Sara I. Pai, Sandrine Faivre, Lisa Licitra, Jean-Pascal Machiels, Jan B. Vermorken, Paolo Bruzzi, Viktor Gruenwald, Raul E. Giglio, C. René Leemans, Tanguy Y. Seiwert, Denis Soulieres

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 96; DOI: 10.1186/s40425-019-0578-0
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle, Emiliano Calvo

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 20; DOI: 10.1186/s40425-019-0510-7
Design considerations for early-phase clinical trials of immune-oncology agents
Nolan A. Wages, Cody Chiuzan, Katherine S. Panageas

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 81; DOI: 10.1186/s40425-018-0389-8
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar, Richard Tuli

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 46; DOI: 10.1186/s40425-018-0361-7
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 8; DOI: 10.1186/s40425-018-0316-z

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical trials